Chapter 1.GLOBAL ONCOLOGY BIOSIMILARS MARKET – Scope & Methodology

1.1. Market Segmentation

1.2. Assumptions

1.3. Research Methodology

1.4. Primary Sources

1.5. Secondary Sources

Chapter 2.GLOBAL ONCOLOGY BIOSIMILARS MARKET – Executive Summary

2.1. Market Size & Forecast – (2023 – 2030) ($M/$Bn)

2.2. Key Trends & Insights

2.3. COVID-19 Impact Analysis

      2.3.1. Impact during 2023 - 2030

      2.3.2. Impact on Supply – Demand

Chapter 3.GLOBAL ONCOLOGY BIOSIMILARS MARKET – Competition Scenario

3.1. Market Share Analysis

3.2. Product Benchmarking

3.3. Competitive Strategy & Development Scenario

3.4. Competitive Pricing Analysis

3.5. Supplier - Distributor Analysis

Chapter 4.GLOBAL ONCOLOGY BIOSIMILARS MARKET - Entry Scenario

4.1. Case Studies – Start-up/Thriving Companies

4.2. Regulatory Scenario - By Region

4.3 Customer Analysis

4.4. Porter's Five Force Model

       4.4.1. Bargaining Power of Suppliers

       4.4.2. Bargaining Powers of Customers

       4.4.3. Threat of New Entrants

       4.4.4. Rivalry among Existing Players

       4.4.5. Threat of Substitutes

Chapter 5. GLOBAL ONCOLOGY BIOSIMILARS MARKET- Landscape

5.1. Value Chain Analysis – Key Stakeholders Impact Analysis

5.2. Market Drivers

5.3. Market Restraints/Challenges

5.4. Market Opportunities

Chapter 6.GLOBAL ONCOLOGY BIOSIMILARS MARKET – By Disease Indication

6.1. Breast Cancer

6.2. Non-Small Cell Lung Cancer

6.3. Colorectal Cancer

6.4. Neutropenia

6.5. Blood Cancer

6.6. Leukaemia

6.7. Others

Chapter 7.GLOBAL ONCOLOGY BIOSIMILARS MARKET– By Distribution Channel

7.1. Hospital Pharmacies

7.2. Retail Pharmacies

7.3. Online Pharmacies

Chapter 8.GLOBAL ONCOLOGY BIOSIMILARS MARKET– By Region

8.1. North America

8.2. Europe

8.3. The Asia Pacific

8.4. Latin America

8.5. The Middle East

8.6. Africa

Chapter 9. GLOBAL ONCOLOGY BIOSIMILARS MARKET– Company Profiles – (Overview, Product Portfolio, Financials, Developments)

9.1. Pfizer Inc. (U.S.)

9.2. GlaxoSmithKline plc (U.K.)

9.3. Novartis AG (Switzerland)

9.4. Mylan N.V. (U.S.)

9.5. Teva Pharmaceutical Industries Ltd. (Israel)

9.6. Sanofi (France)

9.7. F. Hoffmannn-La Roche Ltd. (Switzerland)

9.8. Zydus Cadila (India)

9.9. Lupin (India)

9.10. Amneal Pharmaceuticals LLC. (U.S.)

9.11. Cipla Inc. (U.S.)

9.12. Aurobindo Pharma (India)